Arcutis Biotherapeutics, Inc. (ARQT) is a clinical-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases. With its headquarters located in Westlake Village, California, the company operates with a bold vision of applying biopharmaceutical science to dermatology for the betterment of patients’ health and quality of life.
Arcutis uses innovative technologies to accelerate the discovery and development of significant therapies for a variety of skin conditions. The company's unique approach combines an appreciation for the complexities of skin biology with insight into patients' needs. This thoughtful approach, combined with the technical sophistication and robust drug development capabilities, enables Arcutis to rapidly advance novel molecules into the clinic.
The company's portfolio is focused on immunology and inflammation. Central to this portfolio is ARQ-151 (topical roflumilast cream), an investigational nonsteroidal, once-daily, topical PDE4 inhibitor for the potential treatment of chronic skin conditions such as plaque psoriasis and atopic dermatitis. The drug is currently in Phase 3 clinical trials, with the company also planning to investigate its potential use in seborrheic dermatitis and scalp psoriasis.
In addition to ARQ-151, Arcutis is also developing ARQ-154 (topical roflumilast foam), a potential treatment for common skin disorders such as seborrheic dermatitis and scalp psoriasis, and ARQ-252, a selective JAK1 inhibitor, for hand eczema and vitiligo.
Arcutis Biotherapeutics, Inc. successfully launched its Initial Public Offering (IPO) on January 31, 2020, and currently trades under the ticker symbol ARQT on the Nasdaq Global Market. It's led by an experienced management team with a reputation for successfully pushing forward new treatments to the market and achieving high-value outcomes.
The company truly embodies its motto: 'Dermatology, reimagined'. By placing patients at the center of all operations, Arcutis genuinely believes in unlocking new opportunities to improve patients' lives. Moving forward, the company has plans to continue to leverage novel technologies to discover new molecules that will change the landscape of dermatological treatments.